Under the current guidelines, metformin should be used as a first-line treatment for DM in RA patients or sodium-glucose cotransporter 2 inhibitors (such as empagliflozin) or glucagon-like peptide 1 receptor in those who have established CV disease or are at greater risk for developing it in the future [38]. The gene discussed is SLC5A2; the disease is diabetes mellitus.